PBK and glioblastoma: Either using HI-TOPK-32 as a TOPK inhibitor or knocking down TOPK inhibits the viability of cell growth and sphere formation in human brain tumor-derived glioblastoma stem cells [94], strongly supporting the use of TOPK as a therapeutic target in CSCs and the potential benefits for treating patients with CSC-enriched tumors.